Safety of cyproterone acetate: Report of active surveillance

Pharmacoepidemiology and Drug Safety

Volumn 6, Issue 3, 1997, Pages 169-178

  Heinemann, Lothar A J ^a,b,d   Will Shahab, Liane ^a,b   Van Kesteren, Paul ^c   Gooren, Louis J G ^c  

^a Ctr of Epidemiol and Hlth Res   (Germany)

^b Association for Pharmacoepidemiology   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ZEG Ctr Epidemiol and Hlth Res   (Germany)

Author keywords

Active surveillance; Cyproterone acetate; Follow up study; Liver cancer; Liver toxicity; Pharmacoepidemiology

Indexed keywords

ANDROCUR 50; CHLORMADINONE; CHLORMADINONE ACETATE; CHLORMADINONE ACETATE PLUS MESTRANOL; CYPROTERONE ACETATE; DIANE; ESTROGEN; LIVER ENZYME; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CHILD; DEPRESSION; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FOLLOW UP; GYNECOMASTIA; HUMAN; LIVER CANCER; LIVER TOXICITY; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; MARKETING; MASTALGIA; PHARMACOEPIDEMIOLOGY; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; SEXUAL DEVIATION; TRANSSEXUALISM; VIRILIZATION;

EID: 0030795590     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199705)6:3<169::AID-PDS263>3.0.CO;2-3     Document Type: Article

References (20)

1. Watanabe, S., Yamasaki, S. and Tanae, A. Three cases of hepatocellular carcinoma among cyproterone users (Letter). Lancet; 1994; 344: 1567-1568.
2. Rabe, T., Feldmann, K. and Grunwald, K. Liver tumours in women and oral contraceptives (Letter). Lancet 1994; 344: 1568.
3. Rüdiger, T., Beckmann, J. and Queißer, W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinylestradiol (Letter). Lancet 1995; 345: 452-453.
4. Topinka, J., Andrae, U., Schwarz, L. R. and Wolf, T. Cyproterone acetate generates DNA adducts in rat liver and primary rat hepatocyte cultures. Carcinogenesis 1993; 14: 423-427.
5. ECETOC, Brussels, 1989.
6. Rabe, T., Feldmann, K., Heinemann, L. and Runnebaum, B. Cyproterone acetate. Is it hepatoor genotoxic? Drug Safety 1995; 14: 25-38.
7. Kattan, J., Spatz, A., Culine, S., et al. Hepatocellular carcinoma during hormone therapy for prostatic cancer. American Journal of Clinical Oncology and Cancer Clinical Therapy 1994; 17: 390-392.
8. Ohri, S. K., Caer, J. A. R. and Keane, P. F. Hepatocellular carcinoma and treatment with cyproterone acetate. British Medical Urology 1991; 67: 213-221.
9. Will-Shahab, L. and Heinemann, L. Active Surveillance Study on Patients Treated with CPA Long-Term. SEHOST Project, Research Report. ZEG, Berlin, 1995.
10. Thomas, D. B. Exogenous steroid hormones and hepatocellular carcinoma. In Etiology, Pathology and Treatment of Hepatocellular Carcinoma in North America. Tabor E., DiBisceglie A M., Purcell, R. H. (Eds). Advances in Applied Biotechnology Series, Vol. 13. Gulf Printing Co., Houston, 1991, pp. 77-89.
11. World Health Organization. Oral contraceptives and neoplasia. Report of a WHO Scientific Group. WHO Technical Report Series 817, Geneva, 1992, pp. 22-25.
12. Prentice, R. L. Epidemiologic data on exogeneous hormones and hepatocellular carcinoma and other selected cancers. Preventive Medicine 1991; 20: 38-46.
13. Watanabe, S. and Kotayashi, Y. Exogenous hormones and human cancer Japanese Journal of Clinical Oncology 1993; 23: 1-13.
14. The MILTS Collaborative Research Team (prepared by Heinemann, L, Thomas, D. B. and Möhner, M.). Multicentre international liver tumour study. Research protocol of the case-control study on hepatocellular cancer. Pharmacoepidemiology and Drug Safety 1996; 5: 173-186.
15. Neumann, I., Thierau, D., Andrae, U., Greim, H. and Schwarz, L. R. Cyproterone acetate induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in γ-glutanyltranspeptidase-positive cells. Carcinogenesis 1992; 13: 373-378.
16. WHO. IARC monographs on the evaluation of the carcinogenic risk to humans. Genetic and related effects. An Updating of Selected IARC Monographs from Volumes 1 to 42. Supplementum 6. WHO, IARC, Lyon, 1987.
17. Anonymous. Investigations into the genotoxic potential of cyproterone acetate (CPA) and their relevance for safety assessment. Internal report, Schering AG, Berlin, 4 July 1994.
18. Lawson, D. H. Postmarketing surveillance versus clinical trials: Which benefits the patient? Cardiology 1994; 85(Suppl. 1): 18-23.
19. Guggenmoos-Holzmann, I. Public Health - wozu? Zeitschrift für Allgemeinmedizin 1995; 71: 195-199.
20. Anonymous. Hepatic reactions with cyproterone acetate (Cyprostat, Androcur). Current Problems in Pharmacovigilance 1995; 21: 1.